Oregon's attorney general said Glenmark will pay into a multistate generic-drug antitrust settlement, cooperate against remaining defendants and adopt competition compliance reforms.
What happened
Oregon Attorney General Dan Rayfield and a bipartisan coalition of states announced a $29.6 million settlement with Glenmark over accusations that the drugmaker inflated prices and limited competition for generic prescription drugs.
Oregon's share is just over $316,000, and Glenmark agreed to cooperate in ongoing multistate litigation against 33 corporate defendants and 25 individual executives while adopting internal reforms aimed at antitrust compliance, according to the Oregon Department of Justice.
The deal adds another settlement to the states' long-running generic-drug antitrust campaign. Oregon DOJ said the Glenmark settlement follows settlements with Lannett, Bausch, Apotex and Heritage totaling $66.95 million, as states prepare for a first trial in Hartford, Connecticut.
The release also says customers who bought generic prescription drugs made by Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019 may be eligible for compensation.
The broader state litigation began in 2016, with an initial complaint involving Heritage, 17 other companies and two individuals covering 15 generic drugs. Later complaints targeted Teva Pharmaceuticals and 21 other large generic-drug manufacturers and a separate group of 80 topical generic drugs that the release says accounted for billions of dollars in U.S. sales.
Oregon DOJ says the states' cases rely on cooperating witnesses, more than 20 million documents and phone-record databases involving more than 600 sales and pricing personnel in the generics industry. The packet does not include the settlement agreement, complaints, court filings or any statement from Glenmark, so the allegations and settlement terms remain sourced to the agency release.